$422 Million is the total value of MPM BioImpact LLC's 38 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 18.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $98,051,000 | 0.0% | 7,648,268 | 0.0% | 23.22% | -14.7% | |
| ITOS | iTeos Therapeutics, Inc. | $33,260,000 | -7.5% | 1,745,943 | 0.0% | 7.88% | -21.2% | |
| INBX | Buy | Inhibrx, Inc | $22,976,000 | +97.8% | 1,279,995 | +25.1% | 5.44% | +68.7% |
| VERV | New | Verve Therapeutics, Inc | $21,839,000 | – | 635,792 | +100.0% | 5.17% | – |
| NTLA | Buy | Intellia Therapeutics, Inc. | $20,952,000 | +35.2% | 374,409 | +25.0% | 4.96% | +15.3% |
| RPTX | Repare Therapeutics, Inc. | $19,891,000 | -13.3% | 1,639,849 | 0.0% | 4.71% | -26.1% | |
| GERN | Sell | Geron Corporation | $19,709,000 | +50.7% | 8,422,582 | -0.1% | 4.67% | +28.5% |
| ISEE | New | Iveric Bio Inc | $18,837,000 | – | 1,050,000 | +100.0% | 4.46% | – |
| MRUS | Sell | Merus N.V. | $18,394,000 | -11.6% | 918,310 | -0.1% | 4.36% | -24.7% |
| RGNX | New | REGENXBIO Inc. | $16,362,000 | – | 619,083 | +100.0% | 3.88% | – |
| IOVA | Buy | Iovance Biotherapeutics Inc | $16,286,000 | +22.9% | 1,700,000 | +41.7% | 3.86% | +4.8% |
| HOWL | Werewolf Therapeutics, Inc. | $10,770,000 | +10.3% | 2,388,011 | 0.0% | 2.55% | -6.0% | |
| GTHX | G1 Therapeutics, Inc. | $10,701,000 | +152.8% | 856,798 | 0.0% | 2.53% | +115.5% | |
| CYTK | Sell | Cytokinetics Inc. | $9,361,000 | +22.7% | 193,205 | -0.5% | 2.22% | +4.6% |
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $7,631,000 | +12.9% | 605,663 | -5.2% | 1.81% | -3.8% |
| CRNX | Sell | Crinetics Pharmaceuticals Inc. | $7,163,000 | +4.7% | 364,710 | -0.5% | 1.70% | -10.7% |
| TVTX | Sell | Travere Therapeutics Inc. | $6,812,000 | +1.1% | 276,460 | -0.5% | 1.61% | -13.8% |
| YMAB | Y Mabs Therapeutics, Inc. | $6,398,000 | -4.7% | 443,702 | 0.0% | 1.52% | -18.8% | |
| TCRR | TCR2 Therapeutics, Inc. | $6,068,000 | -37.9% | 3,370,982 | 0.0% | 1.44% | -47.1% | |
| HRMY | Sell | Harmony Biosciences Hldgs Inc. | $6,058,000 | -9.7% | 136,780 | -0.5% | 1.44% | -23.0% |
| ARQT | Sell | Arcutis Biotherapeutics inc | $4,915,000 | -10.8% | 257,185 | -0.5% | 1.16% | -23.9% |
| RETA | Sell | Reata Pharmaceuticals Inc | $4,500,000 | -17.7% | 179,058 | -0.5% | 1.07% | -29.8% |
| FOLD | Sell | Amicus Therapeutics Inc. | $4,102,000 | -22.9% | 392,946 | -20.7% | 0.97% | -34.3% |
| PRVB | Buy | Provention Bio Inc | $3,332,000 | +40.6% | 740,344 | +25.0% | 0.79% | +19.9% |
| HARP | Harpoon Therapeutics, Inc. | $3,101,000 | -49.2% | 3,196,707 | 0.0% | 0.73% | -56.7% | |
| EWTX | New | Edgewise Therapeutics, Inc. | $2,992,000 | – | 304,027 | +100.0% | 0.71% | – |
| MDGL | Sell | Madrigal Pharmaceuticals Inc | $2,908,000 | -9.7% | 44,747 | -0.6% | 0.69% | -23.0% |
| RVMD | Revolution Medicines, Inc. | $2,880,000 | +1.2% | 146,041 | 0.0% | 0.68% | -13.8% | |
| VSTM | Verastem, Inc. | $2,758,000 | -26.7% | 3,244,650 | 0.0% | 0.65% | -37.6% | |
| PHAT | Phathom Pharmaceuticals Inc | $2,142,000 | +31.2% | 193,326 | 0.0% | 0.51% | +11.9% | |
| AVDL | Avadel Pharmaceuticals Plc | $2,066,000 | +105.4% | 412,363 | 0.0% | 0.49% | +75.3% | |
| MIRM | Sell | Mirum Pharmaceuticals Inc. | $2,045,000 | -63.6% | 97,322 | -66.3% | 0.48% | -69.0% |
| ONCR | Oncorus, Inc. | $2,020,000 | -32.6% | 2,377,031 | 0.0% | 0.48% | -42.5% | |
| INZY | Sell | Inozyme Pharma Inc. | $1,772,000 | -44.1% | 661,144 | -0.6% | 0.42% | -52.3% |
| ADCT | ADC Therapeutics, Inc. | $1,612,000 | -39.4% | 334,384 | 0.0% | 0.38% | -48.2% | |
| EPIX | Sell | ESSA Pharma, Inc. | $738,000 | -64.6% | 405,700 | -38.6% | 0.18% | -69.7% |
| AVRO | AVROBIO, Inc. | $416,000 | -30.2% | 647,918 | 0.0% | 0.10% | -40.4% | |
| BDTX | Black Diamond Therapeutics, Inc. | $405,000 | -31.4% | 239,888 | 0.0% | 0.10% | -41.5% | |
| NEO | Exit | Neogenomics Inc. | $0 | – | -135,573 | -100.0% | -0.31% | – |
| KRTX | Exit | Karuna Therapeutics inc | $0 | – | -20,000 | -100.0% | -0.70% | – |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -3,425,202 | -100.0% | -1.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.